Functional antibodies targeting IsaA of staphylococcus aureus augment host immune response and open new perspectives for antibacterial therapy

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 1, 2011, Pages 165-173

  Lorenz, Udo ^a   Lorenz, Birgit ^b   Schmitter, Tim ^b   Streker, Karin ^b   Erck, Christian ^c   Wehland, Jürgen ^c   Nicke, Joachim ^b   Zimmermann, Bastian ^d   Ohlsen, Knut ^b  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^b UNIVERSITY OF WÜRZBURG   (Germany)

^c HELMHOLTZ CENTRE FOR INFECTION RESEARCH   (Germany)

^d Biaffin GmbH and CoKG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOSYLTRANSFERASE; GLYCOSYLTRANSFERASE ISAA; IMMUNOGLOBULIN G1 ANTIBODY; MONOCLONAL ANTIBODY; REACTIVE OXYGEN METABOLITE; UK 66P; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIMICROBIAL THERAPY; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BINDING AFFINITY; CATHETER INFECTION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG TARGETING; FEMALE; HOSPITAL INFECTION; HOUSEKEEPING GENE; IMMUNE RESPONSE; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MOUSE; NEUTROPHIL; NONHUMAN; PHAGOCYTE; PRIORITY JOURNAL; RESPIRATORY BURST; REVIEW; SEPSIS; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION;

ANIMALS; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; MALE; MICE; SEPSIS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS;

EID: 78650660618     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01144-10     Document Type: Review

References (46)

1. Aderem, A. 2003. Phagocytosis and the inflammatory response. J. Infect. Dis. 187(Suppl. 2):S340-S345.
2. Bubeck Wardenburg, J., T. Bae, M. Otto, F. R. Deleo, and O. Schneewind. 2007. Poring over pores: alpha-hemolysin and Panton-Valentine leukocidin in Staphylococcus aureus pneumonia. Nat. Med. 13:1405-1406.
3. Bubeck Wardenburg, J., and O. Schneewind. 2008. Vaccine protection against Staphylococcus aureus pneumonia. J. Exp. Med. 205:287-294.
4. Burnie, J. P., R. C. Matthews, T. Carter, E. Beaulieu, M. Donohoe, C. Chapman, P. Williamson, and S. J. Hodgetts. 2000. Identification of an immunodominant ABC transporter in methicillin-resistant Staphylococcus aureus infections. Infect. Immun. 68:3200-3209.
5. Casadevall, A., E. Dadachova, and L. A. Pirofski. 2004. Passive antibody therapy for infectious diseases. Nat. Rev. Microbiol. 2:695-703.
6. Clarke, S. R., K. J. Brummell, M. J. Horsburgh, P. W. McDowell, S. A. Mohamad, M. R. Stapleton, J. Acevedo, R. C. Read, N. P. Day, S. J. Peacock, J. J. Mond, J. F. Kokai-Kun, and S. J. Foster. 2006. Identification of in vivo-expressed antigens of Staphylococcus aureus and their use in vaccinations for protection against nasal carriage. J. Infect. Dis. 193:1098-1108.
7. Dryla, A., S. Prustomersky, D. Gelbmann, M. Hanner, E. Bettinger, B. Kocsis, T. Kustos, T. Henics, A. Meinke, and E. Nagy. 2005. Comparison of antibody repertoires against Staphylococcus aureus in healthy individuals and in acutely infected patients. Clin. Diagn. Lab. Immunol. 12:387-398.
8. Dubrac, S., and T. Msadek. 2004. Identification of genes controlled by the essential YycG/YycF two-component system of Staphylococcus aureus. J. Bacteriol. 186:1175-1181.
9. Etz, H., D. B. Minh, T. Henics, A. Dryla, B. Winkler, C. Triska, A. P. Boyd, J. Sollner, W. Schmidt, U. von Ahsen, M. Buschle, S. R. Gill, J. Kolonay, H. Khalak, C. M. Fraser, A. von Gabain, E. Nagy, and A. Meinke. 2002. Identification of in vivo expressed vaccine candidate antigens from Staphylococcus aureus. Proc. Natl. Acad. Sci. U. S. A. 99:6573-6578. (Pubitemid 34526174)
10. Fattom, A., S. Fuller, M. Propst, S. Winston, L. Muenz, D. He, R. Naso, and G. Horwith. 2004. Safety and immunogenicity of a booster dose of Staphylococcus aureus types 5 and 8 capsular polysaccharide conjugate vaccine (StaphVAX) in hemodialysis patients. Vaccine 23:656-663.
11. Gresham, H. D., J. H. Lowrance, T. E. Caver, B. S. Wilson, A. L. Cheung, and F. P. Lindberg. 2000. Survival of Staphylococcus aureus inside neutrophils contributes to infection. J. Immunol. 164:3713-3722.
12. Hall, A. E., P. J. Domanski, P. R. Patel, J. H. Vernachio, P. J. Syribeys, E. L. Gorovits, M. A. Johnson, J. M. Ross, J. T. Hutchins, and J. M. Patti. 2003. Characterization of a protective monoclonal antibody recognizing Staphylococcus aureus MSCRAMM protein clumping factor A. Infect. Immun. 71: 6864-6870.
13. Hampton, M. B., A. J. Kettle, and C. C. Winterbourn. 1998. Inside the neutrophil phagosome: oxidants, myeloperoxidase, and bacterial killing. Blood 92:3007-3017.
14. Holtfreter, S., T. T. Nguyen, H. Wertheim, L. Steil, H. Kusch, Q. P. Truong, S. Engelmann, M. Hecker, U. Volker, A. van Belkum, and B. M. Broker. 2009. Human immune proteome in experimental colonization with Staphylococcus aureus. Clin. Vaccine Immunol. 16:1607-1614.
15. Huang, S. S., D. J. Diekema, D. K. Warren, G. Zuccotti, P. L. Winokur, S. Tendolkar, L. Boyken, R. Datta, R. M. Jones, M. A. Ward, T. Aubrey, A. B. Onderdonk, C. Garcia, and R. Platt. 2008. Strain-relatedness of methicillinresistant Staphylococcus aureus isolates recovered from patients with repeated infection. Clin. Infect. Dis. 46:1241-1247.
16. Ishizaka, A., K. Kojima, Y. Sakiyama, S. Matsumoto, K. Kuwajima, Y. Wagatsuma, R. Shibata, and K. Joh. 1992. Hyper-response of serum IgG1 to Staphylococcus aureus peptidoglycan in patients with hyper-IgE syndrome. Clin. Exp. Immunol. 87:53-57.
17. Jungbauer, A., C. Tauer, M. Reiter, M. Purtscher, E. Wenisch, F. Steindl, A. Buchacher, and H. Katinger. 1989. Comparison of protein A, protein G and copolymerized hydroxyapatite for the purification of human monoclonal antibodies. J. Chromatogr. 476:257-268.
18. Kaufman, D. 2006. Veronate (Inhibitex). Curr. Opin. Invest. Drugs 7:172-179.
19. Keller, M. A., and E. R. Stiehm. 2000. Passive immunity in prevention and treatment of infectious diseases. Clin. Microbiol. Rev. 13:602-614.
20. Kelly, J. 2000. Immunotherapy against antibiotic-resistant bacteria: the Russian experience with an antistaphylococcal hyperimmune plasma and immunoglobulin. Microbes Infect. 2:1383-1392.
21. Kelly-Quintos, C., L. A. Cavacini, M. R. Posner, D. Goldmann, and G. B. Pier. 2006. Characterization of the opsonic and protective activity against Staphylococcus aureus of fully human monoclonal antibodies specific for the bacterial surface polysaccharide poly-N-acetylglucosamine. Infect. Immun. 74:2742-2750.
22. Kuklin, N. A., D. J. Clark, S. Secore, J. Cook, L. D. Cope, T. McNeely, L. Noble, M. J. Brown, J. K. Zorman, X. M. Wang, G. Pancari, H. Fan, K. Isett, B. Burgess, J. Bryan, M. Brownlow, H. George, M. Meinz, M. E. Liddell, R. Kelly, L. Schultz, D. Montgomery, J. Onishi, M. Losada, M. Martin, T. Ebert, C. Y. Tan, T. L. Schofield, E. Nagy, A. Meineke, J. G. Joyce, M. B. Kurtz, M. J. Caulfield, K. U. Jansen, W. McClements, and A. S. Anderson. 2006. A novel Staphylococcus aureus vaccine: iron surface determinant B induces rapid antibody responses in rhesus macaques and specific increased survival in a murine S. aureus sepsis model. Infect. Immun. 74:2215-2223.
23. Lorenz, U., C. Huttinger, T. Schafer, W. Ziebuhr, A. Thiede, J. Hacker, S. Engelmann, M. Hecker, and K. Ohlsen. 2008. The alternative sigma factor sigma B of Staphylococcus aureus modulates virulence in experimental central venous catheter-related infections. Microbes Infect. 10:217-223.
24. Lorenz, U., K. Ohlsen, H. Karch, M. Hecker, A. Thiede, and J. Hacker. 2000. Human antibody response during sepsis against targets expressed by methicillin resistant Staphylococcus aureus. FEMS Immunol. Med. Microbiol. 29: 145-153.
25. Lowy, F. D. 1998. Staphylococcus aureus infections. N. Engl. J. Med. 339: 520-532.
26. McDougal, L. K., C. D. Steward, G. E. Killgore, J. M. Chaitram, S. K. McAllister, and F. C. Tenover. 2003. Pulsed-field gel electrophoresis typing of oxacillin-resistant Staphylococcus aureus isolates from the United States: establishing a national database. J. Clin. Microbiol. 41:5113-5120.
27. McKenney, D., K. L. Pouliot, Y. Wang, V. Murthy, M. Ulrich, G. Doring, J. C. Lee, D. A. Goldmann, and G. B. Pier. 1999. Broadly protective vaccine for Staphylococcus aureus based on an in vivo-expressed antigen. Science 284:1523-1527.
28. Menon, K. V., M. S. Whiteley, P. Burden, and R. B. Galland. 1999. Surgical patients with methicillin resistant Staphylococcus aureus infection: an analysis of outcome using P-POSSUM. J. R. Coll. Surg. Edinb. 44:161-163.
29. Monteil, M. A., A. S. Kaniuk, and J. R. Hobbs. 1990. Staphylococcal opsonization and anti-Staphylococcus aureus IgG subclass antibodies in patients with severe or recurrent S. aureus infections. FEMS Microbiol. Immunol. 2:259-262.
30. Murphy, G. J., R. Pararajasingam, A. Nasim, M. J. Dennis, and R. D. Sayers. 2001. Methicillin-resistant Staphylococcus aureus infection in vascular surgical patients. Ann. R. Coll. Surg. Engl. 83:158-163.
31. Ohlsen, K., and U. Lorenz. 2007. Novel targets for antibiotics in Staphylococcus aureus. Future Microbiol. 2:655-666.
32. Patti, J. M. 2004. A humanized monoclonal antibody targeting Staphylococcus aureus. Vaccine 22(Suppl. 1):S39-S43.
33. Pollock, J. D., D. A. Williams, M. A. Gifford, L. L. Li, X. Du, J. Fisherman, S. H. Orkin, C. M. Doerschuk, and M. C. Dinauer. 1995. Mouse model of X-linked chronic granulomatous disease, an inherited defect in phagocyte superoxide production. Nat. Genet. 9:202-209.
34. Projan, S. J., M. Nesin, and P. M. Dunman. 2006. Staphylococcal vaccines and immunotherapy: to dream the impossible dream? Curr. Opin. Pharmacol. 6:473-479.
35. Rupp, M. E., H. P. Holley, Jr., J. Lutz, P. V. Dicpinigaitis, C. W. Woods, D. P. Levine, N. Veney, and V. G. Fowler, Jr. 2007. Phase II, randomized, multicenter, double-blind, placebo-controlled trial of a polyclonal anti-Staphylococcus aureus capsular polysaccharide immune globulin in treatment of Staphylococcus aureus bacteremia. Antimicrob. Agents Chemother. 51:4249-4254.
36. Sakata, N., S. Terakubo, and T. Mukai. 2005. Subcellular location of the soluble lytic transglycosylase homologue in Staphylococcus aureus. Curr. Microbiol. 50:47-51.
37. Schaffer, A. C., R. M. Solinga, J. Cocchiaro, M. Portoles, K. B. Kiser, A. Risley, S. M. Randall, V. Valtulina, P. Speziale, E. Walsh, T. Foster, and J. C. Lee. 2006. Immunization with Staphylococcus aureus clumping factor B, a major determinant in nasal carriage, reduces nasal colonization in a murine model. Infect. Immun. 74:2145-2153.
38. Stapleton, M. R., M. J. Horsburgh, E. J. Hayhurst, L. Wright, I. M. Jonsson, A. Tarkowski, J. F. Kokai-Kun, J. J. Mond, and S. J. Foster. 2007. Characterization of IsaA and SceD, two putative lytic transglycosylases of Staphylococcus aureus. J. Bacteriol. 189:7316-7325.
39. Stranger-Jones, Y. K., T. Bae, and O. Schneewind. 2006. Vaccine assembly from surface proteins of Staphylococcus aureus. Proc. Natl. Acad. Sci. U. S. A. 103:16942-16947.
40. Tao, M., H. Yamashita, K. Watanabe, and T. Nagatake. 1999. Possible virulence factors of Staphylococcus aureus in a mouse septic model. FEMS Immunol. Med. Microbiol. 23:135-146.
41. Tenover, F. C., L. K. McDougal, R. V. Goering, G. Killgore, S. J. Projan, J. B. Patel, and P. M. Dunman. 2006. Characterization of a strain of communityassociated methicillin-resistant Staphylococcus aureus widely disseminated in the United States. J. Clin. Microbiol. 44:108-118.
42. Verkaik, N. J., H. A. Boelens, C. P. de Vogel, M. Tavakol, L. G. Bode, H. A. Verbrugh, A. van Belkum, and W. J. van Wamel. 2010. Heterogeneity of the humoral immune response following Staphylococcus aureus bacteremia. Eur. J. Clin. Microbiol. Infect. Dis. 29:509-518.
43. Vernachio, J., A. S. Bayer, T. Le, Y. L. Chai, B. Prater, A. Schneider, B. Ames, P. Syribeys, J. Robbins, and J. M. Patti. 2003. Anti-clumping factor A immunoglobulin reduces the duration of methicillin-resistant Staphylococcus aureus bacteremia in an experimental model of infective endocarditis. Antimicrob. Agents Chemother. 47:3400-3406.
44. Vernachio, J. H., A. S. Bayer, B. Ames, D. Bryant, B. D. Prater, P. J. Syribeys, E. L. Gorovits, and J. M. Patti. 2006. Human immunoglobulin G recognizing fibrinogen-binding surface proteins is protective against both Staphylococcus aureus and Staphylococcus epidermidis infections in vivo. Antimicrob. Agents Chemother. 50:511-518.
45. von Eiff, C., K. Becker, K. Machka, H. Stammer, and G. Peters. 2001. Nasal carriage as a source of Staphylococcus aureus bacteremia. Study Group. N. Engl. J. Med. 344:11-16. (Pubitemid 32064839)
46. Vytvytska, O., E. Nagy, M. Bluggel, H. E. Meyer, R. Kurzbauer, L. A. Huber, and C. S. Klade. 2002. Identification of vaccine candidate antigens of Staphylococcus aureus by serological proteome analysis. Proteomics 2:580-590. (Pubitemid 34507348)